Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane.
Inhibition of metabolic re-programming represents an attractive approach for prevention of prostate cancer. Studies have implicated increased synthesis of fatty acids or glycolysis in pathogenesis of human prostate cancers. We have shown previously that prostate cancer prevention by sulforaphane (SFN) in Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model is associated with inhibition of fatty acid metabolism. This study utilized human prostate cancer cell lines (LNCaP, 22Rv1, and PC-3), two different transgenic mouse models (TRAMP and Hi-Myc), and plasma specimens from a clinical study to explore the glycolysis inhibition potential of SFN. We found that SFN treatment: (a) decreased real-time extracellular acidification rate in LNCaP, but not in PC-3 cell line ; (b) significantly downregulated expression of hexokinase II (HKII), pyruvate kinase M2 (PKM2), and/or lactate dehydrogenase A (LDHA) in vitro in cells and in vivo in neoplastic lesions in the prostate of TRAMP and Hi-Myc mice; and (c) significantly suppressed glycolysis in prostate of Hi-Myc mice as measured by ex vivo1 H magnetic resonance spectroscopy. SFN treatment did not decrease glucose uptake or expression of glucose transporters in cells. Overexpression of c-Myc, but not constitutively active Akt, conferred protection against SFN-mediated downregulation of HKII and LDHA protein expression and suppression of lactate levels. Examination of plasma lactate levels in prostate cancer patients following administration of a SFN-rich broccoli sprout extract failed to show declines in its levels. Additional clinical trials are needed to determine whether SFN treatment can decrease lactate production in human prostate tumors.